Last reviewed · How we verify
tri-weekly cisplatin
At a glance
| Generic name | tri-weekly cisplatin |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Korea Cancer Center Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer (PHASE2)
- Radical Cystectomy Versus Tri-Modal Therapy for Treatment of cT2N0M0 Urinary Bladder Transitional Cell Carcinoma (NA)
- sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (PHASE1)
- Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC (PHASE2)
- A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer (PHASE1, PHASE2)
- Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC (PHASE2)
- Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (PHASE3)
- Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tri-weekly cisplatin CI brief — competitive landscape report
- tri-weekly cisplatin updates RSS · CI watch RSS
- Korea Cancer Center Hospital portfolio CI